CD274 and neoplasm: Kates et al. evaluated the characterization of the expression of immunity cells among patients with BCG-treated NMIBC: the adaptive immune resistance represented a mechanism of BCG failure, with baseline tumor PD-L1 expression predicting an unfavorable BCG response; if validated, baseline tumor PD-L1 expression might be used to guide therapeutic decision.